Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy. Here we design an ALVAC/Pentavalent B/E/E/E/E vaccine to increase the diversity of gp120 motifs in the immunogen to elicit a broader an...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradley, Todd, Pollara, Justin, Santra, Sampa, Vandergrift, Nathan, Pittala, Srivamshi, Bailey-Kellogg, Chris, Shen, Xiaoying, Parks, Robert, Goodman, Derrick, Eaton, Amanda, Balachandran, Harikrishnan, Mach, Linh V., Saunders, Kevin O., Weiner, Joshua A., Scearce, Richard, Sutherland, Laura L., Phogat, Sanjay, Tartaglia, Jim, Reed, Steven G., Hu, Shiu-Lok, Theis, James F., Pinter, Abraham, Montefiori, David C., Kepler, Thomas B., Peachman, Kristina K., Rao, Mangala, Michael, Nelson L., Suscovich, Todd J., Alter, Galit, Ackerman, Margaret E., Moody, M. Anthony, Liao, Hua-Xin, Tomaras, Georgia, Ferrari, Guido, Korber, Bette T., Haynes, Barton F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472724/
https://www.ncbi.nlm.nih.gov/pubmed/28593989
http://dx.doi.org/10.1038/ncomms15711

Ejemplares similares

Ejemplares similares